Reductions in liver enzyme levels and the resolution of hepatic steatosis were observed, highlighting the therapeutic potential of glucocorticoid receptor antagonism in MASLD associated with hypercortisolism. The gene discussed is NR3C1; the disease is adrenal gland hyperfunction.